Sobi Revenue Surges on Altuvoct, Doptelet Sales; Arthrosi Acquisition Completed
Event summary
- Sobi reported Q1 2026 revenue of SEK 7.184 billion, a 24% increase at CER.
- Hematology revenue, driven by Altuvoct (SEK 1.240 billion) and Doptelet (SEK 1.433 billion), rose 24% at CER.
- Immunology revenue also increased 24% at CER, boosted by Gamifant (SEK 734 million) and Kineret (SEK 779 million).
- Sobi completed the acquisition of Arthrosi Therapeutics, Inc. in Q1 2026.
- Adjusted EBITA margin improved to 38% (excluding IAC of SEK 139 million).
The big picture
Sobi's strong Q1 performance highlights the ongoing demand for specialized treatments in hematology and immunology, areas experiencing robust growth within the biopharmaceutical sector. The acquisition of Arthrosi Therapeutics signals a strategic move to expand Sobi’s pipeline and potentially diversify its revenue streams, though integration challenges are typical in such transactions. The company's valuation will be sensitive to continued execution against its growth targets and the successful integration of Arthrosi.
What we're watching
- Growth Sustainability
- The continued reliance on Altuvoct and Doptelet for a significant portion of revenue raises questions about the sustainability of this growth rate and potential product concentration risk.
- IAC Impact
- The exclusion of Items Affecting Comparability (IAC) significantly boosted the reported EBITA margin; analysts should monitor how these IAC items evolve and impact future profitability.
- Integration Risk
- The Arthrosi acquisition introduces integration risk; the pace at which Arthrosi’s technology or pipeline contributes to Sobi’s overall growth will be a key indicator of the deal’s success.
Related topics